Displaying One Session

Burning Debate Fri, Sep 11, 2020
Moderators
Session Type
Burning Debate
Date
Fri, Sep 11, 2020
Invited Presentations Invited Abstracts

BD02.01 - Presentation 01 (ID 175)

Speakers
Authors
Presentation Number
BD02.01
Presentation Topic
Invited Presentations
Invited Presentations Invited Abstracts

BD02.02 - Presentation 02 (ID 174)

Speakers
Authors
Presentation Number
BD02.02
Presentation Topic
Invited Presentations

Abstract

Abstract

Multiple disease modifying therapies (DMTs) are available for relapsing forms of MS, including active secondary progressive MS (SPMS). Only one DMT is approved for primary progressive MS (PPMS). There is a lack of effective treatments for neurodegeneration injury and progressive MS. Clinical trials remain the fundamental way to establish a treatment benefit.

To date, defining MS by clinical phenotype remains the accepted approach, and we should not abandon this. We need to focus on progressive MS, both active and not active, and document whether therapies can slow neurodegenerative injury. This discussion will make the case for pursuing such trials.

Collapse